胃复春治疗幽门螺杆菌阳性慢性萎缩性胃炎的疗效及对胃液pH、胃蛋白酶原的影响
|
摘要
目的:探究胃复春治疗幽门螺杆菌阳性慢性萎缩性胃炎的疗效及对胃液p H、胃蛋白酶原的影响。方法:选取2014年8月至2016年8月在南京中医药大学附属南京市中西医结合医院老年病科和脾胃病科就诊的幽门螺杆菌阳性慢性萎缩性胃炎患者200例,随机分为对照组和观察组,每组100例。2组患者基础抗幽门螺杆菌治疗均采用标准三联方案,观察组在此基础上给予胃复春片治疗,连续治疗4周。治疗后比较2组胃液p H、幽门螺杆菌阳性率、胃蛋白酶原及疗效。结果:与治疗前比较,治疗后2组胃内p H值均显著升高,观察组高于对照组(P<0.05);与治疗前比较,2组幽门螺杆菌阳性率均显著下降,且观察组低于对照组(P<0.05);与治疗前比较,治疗后2组胃蛋白酶1、2水平均显著升高,且观察组高于对照组(P<0.05);治疗后观察组总有效率为93.83%,较对照组的79.07%显著升高(P<0.05)。结论:胃复春对幽门螺杆菌阳性慢性萎缩性胃炎患者疗效显著,同时提高胃液p H和胃蛋白酶原水平。
Objective: To explore the clinical efficacy of Weifuchun Pill on Helicobacter pylori( H. pylori) positive chronic atrophic gastritis and effects on p H and pepsinogen in gastric juice. Methods: A total of 200 patients with H. pylori positive chronic atrophic gastritis treated in the Department of Geriatrics and the Department of Spleen and Stomach Diseases of Affiliated Hospital of Integrated Traditional Chinese and Western Medicine of Nanjing University of Chinese Medicine from August 2014 to August 2016 were selected and randomly divided into control group and study group,with 100 cases in each group. In both groups,the basic antiHelicobacter pylori treatment was performed by standard triple therapy,and the observation group was given Weifuchun tablets on the basis of this treatment for 4 weeks. After treatment,the gastric juice p H,Helicobacter pylori positive rate,pepsinogen and curative efficacy were compared between 2 groups. Results: Compared with before treatment,the level of p H in stomach of both groups was increased significantly after the treatment,and the study group increased more than the control group( P < 0. 01). Compared with before treatment,the positive rate of Helicobacter pylori in both groups was decreased significantly,and the study group decreased more than the control group( P < 0. 01). The levels of pepsin 1 and 2 in the 2 groups were significantly increased,and the study group increased more than that of the control group( P < 0. 01). After treatment,the total effective rate of the study group was93. 83%,which was significantly higher than that of the control group( 79. 07%)( P < 0. 01). Conclusion: Weifuchun Pills has significant clinical effects on Helicobacter pylori positive chronic atrophic gastritis,and can improve gastric juice p H and pepsinogen levels.
Objective: To explore the clinical efficacy of Weifuchun Pill on Helicobacter pylori( H. pylori) positive chronic atrophic gastritis and effects on p H and pepsinogen in gastric juice. Methods: A total of 200 patients with H. pylori positive chronic atrophic gastritis treated in the Department of Geriatrics and the Department of Spleen and Stomach Diseases of Affiliated Hospital of Integrated Traditional Chinese and Western Medicine of Nanjing University of Chinese Medicine from August 2014 to August 2016 were selected and randomly divided into control group and study group,with 100 cases in each group. In both groups,the basic antiHelicobacter pylori treatment was performed by standard triple therapy,and the observation group was given Weifuchun tablets on the basis of this treatment for 4 weeks. After treatment,the gastric juice p H,Helicobacter pylori positive rate,pepsinogen and curative efficacy were compared between 2 groups. Results: Compared with before treatment,the level of p H in stomach of both groups was increased significantly after the treatment,and the study group increased more than the control group( P < 0. 01). Compared with before treatment,the positive rate of Helicobacter pylori in both groups was decreased significantly,and the study group decreased more than the control group( P < 0. 01). The levels of pepsin 1 and 2 in the 2 groups were significantly increased,and the study group increased more than that of the control group( P < 0. 01). After treatment,the total effective rate of the study group was93. 83%,which was significantly higher than that of the control group( 79. 07%)( P < 0. 01). Conclusion: Weifuchun Pills has significant clinical effects on Helicobacter pylori positive chronic atrophic gastritis,and can improve gastric juice p H and pepsinogen levels.
引文
[1]ObleagCV,Vere CC,Ptra爧cu AM,et al.Severe upper gastrointestinal bleeding determined by a gastric lymphoma associated with Helicobacter pylori-positive atrophic gastritis[J].Rom J Morphol Embryol,2017,58(2):611-617.
[2]Huang J,Zagai U,Hallmans G,et al.Helicobacter pylori infection,chronic corpus atrophic gastritis and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition(EPIC)cohort:A nested case-control study[J].Int J Cancer,2017,140(8):1727-1735.
[3]Jeong S,Choi E,Petersen CP,et al.Distinct metaplastic and inflammatory phenotypes in autoimmune and adenocarcinoma-associated chronic atrophic gastritis[J].United European Gastroenterol J,2017,5(1):37-44.
[4]中华中医药学会脾胃病分会.慢性萎缩性胃炎中医诊疗共识意见(2009,深圳)[J].中国中西医结合消化杂志,2010,18(5):345-349.
[5]韩冬.益气化瘀解毒方对HP相关性慢性萎缩性胃炎临床疗效及胃蛋白酶原的影响[J].中国中西医结合消化杂志,2017,25(1):23-26.
[6]中国中西医结合学会消化系统疾病专业委员会.慢性胃炎的中西医结合诊治方案(草案)[J].中国中西医结合杂志,2005,25(2):172-176.
[7]Tahara T,Tahara S,Tuskamoto T,et al.Magnifying NBI Patterns of Gastric Mucosa After Helicobacter pylori Eradication and Its Potential Link to the Gastric Cancer Risk[J].Dig Dis Sci,2017,62(9):2421-2427.
[8]Di SA,Biagi F,Lenzi M,et al.Clinical usefulness of serum antibodies as biomarkers of gastrointestinal and liver diseases[J].Dig Liver Dis,2017,49(9):947-956.
[9]Lahner E,Gentile G,Purchiaroni F,et al.Single nucleotide polymorphisms related to vitamin B12 serum levels in autoimmune gastritis patients with or without pernicious anaemia[J].Dig Liver Dis,2015,47(4):285-290.
[10]Mrginean MO,Mrginean CO,Meli爫LE,et al.The impact of host's genetic susceptibility on Helicobacter pylori infection in children[J].Medicine(Baltimore),2017,96(30):e7612.
[11]宋晨雪,王昱博,刘传贵,等.传统中药联合标准三联疗法治疗幽门螺杆菌诱发的慢性非萎缩性胃炎及其作用机制[J].吉林大学学报:医学版,2016,42(4):789-792.
[12]Li Z,Wu C,Li L,et al.Effect of long-term proton pump inhibitor administration on gastric mucosal atrophy:A meta-analysis[J].Saudi J Gastroenterol,2017,23(4):222-228.
[13]Kotachi T,Ito M,Yoshihara M,et al.Serological Evaluation of Gastric Cancer Risk Based on Pepsinogen and Helicobacter pylori Antibody:Relationship to Endoscopic Findings[J].Digestion,2017,95(4):314-318.
[14]Liu Y,Zhang Y,Guo H,et al.Accelerated digestion of nucleic acids by pepsin from the stomach of chicken[J].Br Poult Sci,2016,57(5):674-681.
[15]毛军民,石镇东,匡清清,等.调和化瘀解毒法治疗慢性萎缩性胃炎疗效观察[J].现代中西医结合杂志,2015,24(23):2516-2518,2535.
[16]张琴芬,任慕兰,赵维英,等.红参中人参总皂苷联合雷公藤红素体内外抗卵巢癌作用评价[J].中成药,2017,39(1):170-176.
[17]郭国英,王瑞华,张明.胃复春对慢性萎缩性胃炎肠化生及胃粘膜COX-2蛋白表达的影响[J].中国药物经济学,2012,7(1):25-27.
[18]Jang SH,Lee H,Kim JS,et al.Association between Helicobacter pylori Infection and Cerebral Small Vessel Disease[J].Korean J Fam Med,2015,36(5):227-232.
[19]陈曦,赵亚红,张也青,等.胃复春的临床应用和现代研究进展[J].江西中医药,2016,47(9):77-80.
[2]Huang J,Zagai U,Hallmans G,et al.Helicobacter pylori infection,chronic corpus atrophic gastritis and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition(EPIC)cohort:A nested case-control study[J].Int J Cancer,2017,140(8):1727-1735.
[3]Jeong S,Choi E,Petersen CP,et al.Distinct metaplastic and inflammatory phenotypes in autoimmune and adenocarcinoma-associated chronic atrophic gastritis[J].United European Gastroenterol J,2017,5(1):37-44.
[4]中华中医药学会脾胃病分会.慢性萎缩性胃炎中医诊疗共识意见(2009,深圳)[J].中国中西医结合消化杂志,2010,18(5):345-349.
[5]韩冬.益气化瘀解毒方对HP相关性慢性萎缩性胃炎临床疗效及胃蛋白酶原的影响[J].中国中西医结合消化杂志,2017,25(1):23-26.
[6]中国中西医结合学会消化系统疾病专业委员会.慢性胃炎的中西医结合诊治方案(草案)[J].中国中西医结合杂志,2005,25(2):172-176.
[7]Tahara T,Tahara S,Tuskamoto T,et al.Magnifying NBI Patterns of Gastric Mucosa After Helicobacter pylori Eradication and Its Potential Link to the Gastric Cancer Risk[J].Dig Dis Sci,2017,62(9):2421-2427.
[8]Di SA,Biagi F,Lenzi M,et al.Clinical usefulness of serum antibodies as biomarkers of gastrointestinal and liver diseases[J].Dig Liver Dis,2017,49(9):947-956.
[9]Lahner E,Gentile G,Purchiaroni F,et al.Single nucleotide polymorphisms related to vitamin B12 serum levels in autoimmune gastritis patients with or without pernicious anaemia[J].Dig Liver Dis,2015,47(4):285-290.
[10]Mrginean MO,Mrginean CO,Meli爫LE,et al.The impact of host's genetic susceptibility on Helicobacter pylori infection in children[J].Medicine(Baltimore),2017,96(30):e7612.
[11]宋晨雪,王昱博,刘传贵,等.传统中药联合标准三联疗法治疗幽门螺杆菌诱发的慢性非萎缩性胃炎及其作用机制[J].吉林大学学报:医学版,2016,42(4):789-792.
[12]Li Z,Wu C,Li L,et al.Effect of long-term proton pump inhibitor administration on gastric mucosal atrophy:A meta-analysis[J].Saudi J Gastroenterol,2017,23(4):222-228.
[13]Kotachi T,Ito M,Yoshihara M,et al.Serological Evaluation of Gastric Cancer Risk Based on Pepsinogen and Helicobacter pylori Antibody:Relationship to Endoscopic Findings[J].Digestion,2017,95(4):314-318.
[14]Liu Y,Zhang Y,Guo H,et al.Accelerated digestion of nucleic acids by pepsin from the stomach of chicken[J].Br Poult Sci,2016,57(5):674-681.
[15]毛军民,石镇东,匡清清,等.调和化瘀解毒法治疗慢性萎缩性胃炎疗效观察[J].现代中西医结合杂志,2015,24(23):2516-2518,2535.
[16]张琴芬,任慕兰,赵维英,等.红参中人参总皂苷联合雷公藤红素体内外抗卵巢癌作用评价[J].中成药,2017,39(1):170-176.
[17]郭国英,王瑞华,张明.胃复春对慢性萎缩性胃炎肠化生及胃粘膜COX-2蛋白表达的影响[J].中国药物经济学,2012,7(1):25-27.
[18]Jang SH,Lee H,Kim JS,et al.Association between Helicobacter pylori Infection and Cerebral Small Vessel Disease[J].Korean J Fam Med,2015,36(5):227-232.
[19]陈曦,赵亚红,张也青,等.胃复春的临床应用和现代研究进展[J].江西中医药,2016,47(9):77-80.